A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD), the devastating and most prevailing underlying cause for age-associated dementia, has no effective disease-modifying treatment. The last approved drug for the relief of AD symptoms was in 2003. The recent approval of sodium oligomannate (GV-971, 2019) in China and the human antibody aducanumab in the USA (ADUHELM, 2021) therefore represent significant breakthroughs, albeit ones that are fraught with controversy. Here, we explore potential scientific ethics issues associated with GV-971 and aducanumab's development and approval. While these issues may be belied by socioeconomic and political complexities in the heady business of commercial drug development, they are of fundamental importance to scientific integrity and ultimately, welfare of patients. We posit that the push for approval of both AD drugs based on incomplete research and unconvincing marginal effectiveness is ethically unsound. Regardless of how both these drugs shall perform in the market for the years to come, the scientific ethics issues and potentially questionable research practices should therefore be duly noted and lessons learned.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium oligomannate (9, GV-971), an oligosaccharide extracted from marine algae, was conditionally approved in China in 2019 amidst ongoing debates regarding its mechanism of action and therapeutic efficacy.54,413”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [413]
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In accordance to the amyloid cascade hypothesis (Hardy & Higgins, 1992), AD stems from amyloid-β, which dyshomeostasis leads to the formation neurotoxic oligomers and insoluble fibrils, which deposit as amyloid plaques that could elicit proinflammatory neuronal cell death.”
BackgroundScheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 3×
“Another Phase Ib trial (PRIME) with monthly intravenous infusions of aducanumab of four fixed doses of 1 mg/kg to 10 mg/kg) over a year showed a reduction in brain amyloid-β load (best with the highest dose of 10 mg/kg), which was accompanied by a measurable slowing of clinical decline as measured by Clinical Dementia…”
BackgroundMethodInfluentialSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“However, despite intensive efforts in the therapeutics development, the disease has had no effective disease-modifying treatment (Cummings et al., 2014).”
BackgroundTwo Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Molecular hybridization: a powerful tool for multitarget drug discovery
de Sena Murteira Pinheiro, P., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 204
Recent progress of nanomedicine in the treatment of Alzheimer’s disease
Hu, L., Tao, Y., Jiang, Y., & Qin, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1228679 · Cited by 52
Su, Y., Liu, N., Sun, R., Ma, J., Li, Z., Wang, P., Ma, H., Sun, Y., Song, J., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1115387 · Cited by 36
“Aducanumab is currently very controversial in clinical application (Yeo-Teh and Tang, 2023).”
BackgroundLi, J., Hao, Y., Wang, S., Li, W., Yue, S., Duan, X., Yang, Y., & Li, B. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117195 · Cited by 22
Metadata
- Authors
- Yeo-Teh, N. S. L., & Tang, B. L.
- Affiliations
- National University of Singapore (SG)
- Corresponding author
- Yeo-Teh, Nicole Shu Ling
- Tang, Bor Luen
- Venue
- Science and Engineering Ethics
- Published
- 2023-01-10
- Volume
- 29
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1353-3452 (ISSN-L)
- 1471-5546
- OpenAlex
- W4315436196
- Cited by
- 28
- References
- 49
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 9 · 2023: 9
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Science and Engineering Ethics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- Alzheimer's disease, scientific ethics, drug approval, aducanumab, ADEME, questionable research practices, scientific integrity, drug development, dementia treatment
- MeSH terms
- Alzheimer Disease, China, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease. https://app.cochat.ai/papers/10.1007/s11948-022-00422-0
- The paper
- Yeo-Teh, N. S. L., & Tang, B. L. (2023). A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease. Science and Engineering Ethics. https://doi.org/10.1007/s11948-022-00422-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.